53086-52-5

Basic information

• Product Name: 2-(3-Bromophenyl)propanoic acid
• Synonyms: 2-M-BROMOPHENYLPROPIONIC ACID;2-(3-bromophenyl)propanoicacid;2-(3-BroMophenyl)Propionic Acid
• CAS NO: 53086-52-5
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07
• Mol File: 53086-52-5.mol

Chemical Properties

• Boiling Point: 319.6 °C at 760 mmHg
• Flash Point: 147.1 °C
• Appearance: /
• Density: 1.523 g/cm³
• Vapor Pressure: 0.000139mmHg at 25°C
• Refractive Index: 1.575
• Solubility: DCM, DMSO, Diethyl Ether, Methanol
• PKA: 4.17±0.10(Predicted)
• CAS DataBase Reference: 2-(3-Bromophenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Bromophenyl)propanoic acid(53086-52-5)
• EPA Substance Registry System: 2-(3-Bromophenyl)propanoic acid(53086-52-5)

Safety Data

• Hazardous Substances Data: 53086-52-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-Bromophenyl)propanoic acid is used as a chemical intermediate for the synthesis of Ketoprofen (K200800) and its related compounds. It plays a crucial role in the production of NSAIDs, which are widely used for their analgesic, antipyretic, and anti-inflammatory properties, helping to manage pain and reduce inflammation in various conditions.

InChI:InChI=1/C9H9BrO2/c1-6(9(11)12)7-3-2-4-8(10)5-7/h2-6H,1H3,(H,11,12)

Upstream product

• 74-88-4 methyl iodide 
• 1878-67-7 3-Bromophenylacetic acid 
• 124-38-9 carbon dioxide 
• 2725-82-8 1-bromo-3-ethylbenzene 

Downstream Products

• 1071454-63-1 2-{3-[3-(2-methoxy-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazolo[3,4-b]pyridin-5-yl]-phenyl}-propionic acid 
• 1146411-14-4 (S)-2-(3-bromophenyl)-propionic acid 

Relevant articles and documents

NOVEL THIAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention provides a novel thiazole derivative or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The thiazole derivative or a pharmaceutically acceptable salt thereof according to the present invention has selective inhibitory activity against cyclin-dependent kinase (CDK) and thus can be usefully used as a preventive or therapeutic agent for various diseases associated with the CDK.

Photocarboxylation of Benzylic C-H Bonds

The carboxylation of sp3-hybridized C-H bonds with CO2 is a challenging transformation. Herein, we report a visible-light-mediated carboxylation of benzylic C-H bonds with CO2 into 2-arylpropionic acids under metal-free conditions. Photo-oxidized triisopropylsilanethiol was used as the hydrogen atom transfer catalyst to afford a benzylic radical that accepts an electron from the reduced form of 2,3,4,6-tetra(9H-carbazol-9-yl)-5-(1-phenylethyl)benzonitrile generated in situ. The resulting benzylic carbanion reacts with CO2 to generate the corresponding carboxylic acid after protonation. The reaction proceeded without the addition of any sacrificial electron donor, electron acceptor or stoichiometric additives. Moderate to good yields of the desired products were obtained in a broad substrate scope. Several drugs were successfully synthesized using the novel strategy.

SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS

The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.

Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's disease

γ-Secretase modulators (GSMs) are potentially disease-modifying treatments for Alzheimer's disease. They selectively lower pathogenic Aβ42 levels by shifting the enzyme cleavage sites without inhibiting γ-secretase activity, possibly avoiding known adverse effects observed with complete inhibition of the enzyme complex. A cell-based HTS effort identified the sulfonamide 1 as a GSM lead. Lead optimization studies identified compound 25 with improved cell potency, PKDM properties, and it lowered Aβ42 levels in the cerebrospinal fluid (CSF) of Sprague-Dawley rats following oral administration. Further optimization of 25 to improve cellular potency is described.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

FUSED RING HETEROCYCLE KINASE MODULATORS

The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

Tunable phosphinite, phosphite and phosphoramidite ligands for the asymmetric hydrovinylation reactions

Only a limited number of ligands have been successfully employed for the Ni-catalyzed asymmetric hydrovinylation reaction. Diarylphosphinites, carrying β-acylamino groups prepared from readily available carbohydrates, in conjunction with highly dissociated counteranions {[(3,5-(CF3) 2C6H3]4B- or SbF 6-}, effect the hydrovinylation of vinylarenes under ambient pressure of ethylene with high enantioselectivity. Nitrogen substituents such as -COCF3 and COPh groups lead to isomerization of the primary products (3-arylbutenes) to Z- and E-2-aryl-2-butenes. In a prototypical synthesis of a 2-arylproionic acid, (S)-3-(4-bromophenyl)-1-butene (89% ee) has be transformed into (R)-ibuprofen by Ni-catalyzed cross-coupling with i-BuMgBr, followed by oxidation of the double bond with NaIO4 and KMnO 4. Asymmetric codimerization of norbonene and ethylene using binaphthol-derived phosphoramidites as ligands gives 1:1, 2:1 or polymeric adducts depending on the relative configurations and nature of the BINAP and amine moieties. With one of the phosphoramidite-Ni complexes, counteranions BAr4- [Ar=3,5-(CF3)2C 6H3] and SbF6-, which had been used interchangeably in other reactions, give either a 1:1 adduct or a 2:1 adduct, respectively.

Process for preparing hetero aryl and aryl alkanoic acids

An aqueous solution comprising an alkali hydroxide, an aryl or a hetero aryl amine, substituted in ortho position by an alkanoic group and in para position by an inductive electron withdrawing atom or group, and an alkali nitrite is reacted with a mineral acid and hypophosphorous acid in an aqueous medium to afford an aryl and a heteroaryl alkanoic acid substituted in meta position by an electron withdrawing atom or group.